CANCER ADVANCES
Cancer Advances is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio. Cancer Advances is a wholly owned subsidiary of Cato BioVentures. The company's lead compound, Polyclonal Antibody Stimulator (PAS), is an immunomodulator used to treat gastrointestinal cancer. Please visit their Product page for more information on what is in development.
CANCER ADVANCES
Industry:
Biotechnology
Address:
Durham, North Carolina, United States
Country:
United States
Website Url:
http://www.canceradvancesinc.com
Status:
Closed
Contact:
919-361-2286
Email Addresses:
[email protected]
Technology used in webpage:
Microsoft Exchange Online Google Maps Amazon Route 53 Network Solutions
Current Employees Featured
Official Site Inspections
http://www.canceradvancesinc.com
Unable to get host informations!!!
More informations about "Cancer Advances"
About - Cancer Advances
About Cancer Advances, Inc., is a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers and other cancers. The company is focused on โฆ See details»
Cancer Advances - Crunchbase Company Profile
Cancer Advances is a biotechnology company focused on impacting human health and the progression of gastrointestinal cancers by enhancing the โฆ See details»
Cancer Advances 2025 Company Profile: Valuation, โฆ
Information on valuation, funding, cap tables, investors, and executives for Cancer Advances. Use the PitchBook Platform to explore the full profile. See details»
Cancer Advances, Inc. - LinkedIn
Cancer Advances, Inc. Biotechnology Research Durham, North Carolina 100 followers Cancer Advances is dedicated to pioneering new medicines and redefining possibilities for cancer โฆ See details»
Cancer Advances Inc · 4364 S Alston Ave, Durham, NC 27713-2220 โฆ
CANCER ADVANCES INC is an entity in Durham, North Carolina registered with the System for Award Management (SAM) of U.S. General Services Administration (GSA). The entity was โฆ See details»
Cancer Advances, Inc. - Drug pipelines, Patents, Clinical trials
Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers. About Cancer Advances, Inc. Cancer Advances Inc. (Durham, NC) is a biotechnology โฆ See details»
Cancer Advances Company Profile - Office Locations, Competitors โฆ
Cancer Advances has 5 employees at their 1 location. See insights on Cancer Advances including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. See details»
Cancer Advances Inc. - VentureRadar
Cancer Advances, a subsidiary of Cato Bioventures, develops immunomodulator therapeutics to treat gastrointestinal cancers. ... Find out more about Cancer Advances Inc., Therapeutics, โฆ See details»
Contact | Cancer Advances
Westpark Corporate Center 4364 South Alston Avenue Suite 105 Durham, North Carolina USA 27713 See details»
Cancer Advances, Inc. - Phone, Email, Employees, CEO, VP, 2022
Cancer Advances, Inc. (https://www.canceradvancesinc.com) location in North Carolina, United States , revenue, industry and description. Find related and similar companies as well as โฆ See details»
Cancer Advances Acquires the Intellectual Property for a Suite of ...
DURHAM, N.C., Feb. 2 /PRNewswire/ -- Cancer Advances, Inc. (Cancer Advances), a Cato BioVentures portfolio company, announced today that it has completed its acquisition of all the โฆ See details»
Cancer Advances Inc. :: North Carolina (US) :: OpenCorporates
Free and open company data on North Carolina (US) company Cancer Advances Inc. (company number 1045342), 2626 Glenwood Avenue,, Suite 550, Raleigh, NC, 27608 See details»
Cancer Advances, Inc. - Company Profile & Staff Directory
Cancer Advances, Inc. is a Biotechnology company located in Durham US with 2 employees. Access Cancer Advances, Inc.'s email format and Cancer Advances, Inc. staff directory for โฆ See details»
News & Events - Cancer Advances
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) โ Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, โฆ See details»
Cancer Advances, Inc. Announces Abstract at AACR
Mar 23, 2021 Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by โฆ See details»
Cancer Advances
Cancer Advances is focused on developing therapeutics for gastrin/ gastrin receptor (CCKB) producing tumors. The companyโs lead product, Polyclonal Antibody Stimulator (PAS), is an โฆ See details»
Press Releases | Cancer Advances
Dec 6, 2021 Apr 7, 2021 | Press Releases Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, announces โฆ See details»
Cancer Advances, Inc. Announces Issuance of New U.S. Patent
DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) โ Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, โฆ See details»
Cancer Advances-Hill Publishing Group
Nov 18, 2024 Cancer Advances-Hill Publishing GroupAbout this Journal Cancer Advances publishes regular papers and special issues on specific topics of interest to international โฆ See details»
Our Science - Cancer Advances
The incidence of pancreatic cancer is increasing signi๏ฌ-cantly and will soon become the second leading cause of cancer-related deaths in the United States. We have previ-ously shown that โฆ See details»